Chorale Du Centre Hospitalier De Lens

The oncology department at Chorale Du Centre Hospitalier De Lens is dedicated to advancing care for patients with acute lymphoblastic leukemia, multiple myeloma, and other blood‑derived cancers, as well as solid tumor challenges such as metastatic colorectal cancer.

• Frontline immunotherapy integration for adult ALL
• Novel antibody‑drug combinations for relapsed follicular lymphoma
• Subcutaneous daratumumab strategies for frail myeloma patients

Ongoing collaborations with national cancer networks support the pursuit of more effective, patient‑centered treatment options.

Research at the site targets disorders of the blood and lymphatic systems, focusing on B‑cell malignancies and strategies to improve survival after stem‑cell transplantation.

• Early incorporation of targeted agents in high‑risk ALL
• Evaluation of EZH2‑directed therapy in relapsed follicular lymphoma
• Optimization of conditioning regimens for allogeneic transplant

The multidisciplinary team combines hematology expertise with cutting‑edge translational research.

The centre conducts trials that modulate immune pathways in conditions such as Crohn’s disease, assessing newer biologics against established therapies.

• Vedolizumab versus intensified adalimumab for refractory Crohn’s disease
• Exploration of immune checkpoint inhibition in lymphoma
• Biomarker‑guided treatment adjustments in inflammatory bowel disease

These studies aim to reduce disease activity while preserving quality of life for chronic immune patients.

Investigations include neurodegenerative disorders, notably a trial evaluating the impact of caffeine on cognitive decline in early‑to‑moderate Alzheimer’s disease.

• Cognitive outcomes after 30‑week caffeine supplementation
• Biomarker monitoring of disease progression
• Safety profiling in elderly participants

The research contributes to emerging non‑pharmacologic strategies for dementia care.

Clinical work addresses both inflammatory and malignant gastrointestinal conditions, including metastatic colorectal cancer and refractory Crohn’s disease.

• Second‑line FOLFOX/FOLFIRI plus targeted agents for colorectal metastasis
• Therapeutic escalation in Crohn’s disease with loss of response
• Imaging‑guided assessment of treatment efficacy

The aim is to improve survival and symptom control for patients with complex digestive disorders.

The hospital evaluates peri‑operative interventions for heart conditions, such as the use of levosimendan before tricuspid valve surgery to prevent low cardiac output syndrome.

• Pre‑operative levosimendan versus placebo in tricuspid regurgitation surgery
• Assessment of postoperative cardiac performance
• Monitoring of heart‑rate modulation strategies

Findings may shape guidelines for managing right‑ventricular dysfunction in cardiac surgery.

Trials focus on severe infections, including septic shock with hypercontractility and acute kidney injury, testing interventions that could reduce mortality and organ damage.

• Landiolol versus standard care for septic shock mortality
• High‑dose vitamin B3 supplementation to prevent kidney events
• Impact of RAAS inhibition on outcomes after acute kidney injury

The research seeks to improve critical‑care protocols and long‑term recovery for ICU patients.

When a disease does not fit a single category, the site embraces a multicenter, cross‑disciplinary approach, integrating oncology, cardiology, nephrology, and neurology expertise.

• Collaborative trials spanning multiple therapeutic areas
• Integrated data platforms for comprehensive outcome analysis
• Patient‑centered enrollment across diverse clinical specialties

This flexible framework enables rapid initiation of innovative studies that address unmet medical needs.